Tigecycline Dosing in Necrotizing Fasciitis with Severe Renal Impairment on Hemodialysis
No dose adjustment of tigecycline is required for patients with severe renal impairment (creatinine clearance 4 mL/min) or those receiving intermittent hemodialysis—use the standard dosing regimen of 100 mg loading dose followed by 50 mg IV every 12 hours. 1, 2
Pharmacokinetic Rationale
Tigecycline elimination is primarily hepatobiliary (59% fecal excretion), with only 22% excreted unchanged in urine 1. This makes renal function largely irrelevant to tigecycline dosing:
- In patients with severe renal impairment (CrCl <30 mL/min), tigecycline clearance is reduced by only ~20%, with AUC increased by ~30%—clinically insignificant changes that do not warrant dose adjustment 2
- Tigecycline is not efficiently removed by hemodialysis and can be administered without regard to timing of dialysis sessions 1, 2
- Population pharmacokinetic studies in critically ill patients on continuous renal replacement therapy (CRRT) confirm that dialysis clearance contributes minimally to total tigecycline elimination (CRRT clearance 1.69-2.71 L/h versus body clearance of 18.3 L/h) 3
Recommended Dosing for Necrotizing Fasciitis
For necrotizing fasciitis specifically, consider HIGH-DOSE tigecycline: 100 mg IV every 12 hours (after standard 100 mg loading dose) 4, 5, 6, 7
Justification for High-Dose Regimen:
- Necrotizing fasciitis is a life-threatening complicated skin and soft tissue infection (cSSSI) requiring aggressive antimicrobial therapy
- Standard-dose tigecycline (50 mg q12h) may be inadequate for cSSSI caused by less-susceptible organisms (MIC >0.5 mg/L) 7
- A prospective study of 50 NSTI patients treated with tigecycline showed 90.2% clinical cure/improvement rates, though 34% had resistant pathogens including MRSA 5
- High-dose tigecycline (100 mg q12h) is specifically recommended for ventilator-associated pneumonia and infections with drug-resistant organisms 4, 6
Critical Caveats and Monitoring
Hepatic Function Takes Priority:
- If the patient has severe hepatic impairment (Child-Pugh C), reduce maintenance dose to 25 mg IV q12h regardless of renal status 1
- Bilirubin and liver enzymes are the relevant covariates affecting tigecycline clearance, not creatinine 3, 6, 7
Combination Therapy Strongly Recommended:
- Do not use tigecycline monotherapy for necrotizing fasciitis—combine with other agents based on culture results and clinical severity 5
- In the NSTI study, 34% received combination regimens with improved outcomes 5
- Tigecycline has documented inferiority for bloodstream infections and urinary tract infections compared to other agents 4, 8
Black Box Warning Considerations:
- Tigecycline carries an FDA black box warning for increased all-cause mortality (0.6% absolute risk increase) 1
- Reserve tigecycline for situations when alternative treatments are not suitable, which applies to necrotizing fasciitis with multidrug-resistant organisms 1
Practical Administration
- Timing relative to hemodialysis is irrelevant—administer on your standard q12h schedule 1, 2
- Infuse over 30-60 minutes 1
- Duration: 5-14 days for cSSSI, guided by clinical response and source control 1
- Surgical debridement remains the cornerstone of treatment—antibiotics are adjunctive 5
Summary Algorithm
- Standard renal dosing: 100 mg loading → 50 mg IV q12h (hemodialysis irrelevant)
- Consider high-dose: 100 mg loading → 100 mg IV q12h for severe NSTI or resistant organisms
- Check liver function: If Child-Pugh C, reduce to 25 mg q12h maintenance
- Always combine: Add beta-lactam, vancomycin, or other agents based on Gram stain/cultures
- Aggressive surgery: Early and repeated debridement is non-negotiable